Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Shares Outstanding (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Shares Outstanding data on record, last reported at $9.3 million in Q2 2025.

  • For Q2 2025, Shares Outstanding rose 117.69% year-over-year to $9.3 million; the TTM value through Jun 2025 reached $9.3 million, up 117.69%, while the annual FY2024 figure was $9.2 million, 116.11% up from the prior year.
  • Shares Outstanding reached $9.3 million in Q2 2025 per VRCA's latest filing, up from $9.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $42.0 million in Q1 2023 and bottomed at $105144.0 in Q1 2021.
  • Average Shares Outstanding over 5 years is $13.7 million, with a median of $6.7 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding: tumbled 99.74% in 2023, then surged 3944.47% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $27.6 million in 2021, then surged by 49.14% to $41.2 million in 2022, then crashed by 89.68% to $4.3 million in 2023, then surged by 116.11% to $9.2 million in 2024, then increased by 0.83% to $9.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $9.3 million in Q2 2025, $9.2 million in Q1 2025, and $9.2 million in Q4 2024.